Abstract
TGFβ overexpression in human cancer cells has been shown to promote tumor progression. In the present study, we sought to determine whether sequestration of endogenous TGFβ by the expression of a soluble TGFβ type III receptor (sRIII), can reduce malignancy in human carcinoma cells and whether the tumor-suppressive activity of sRIII is associated with the inhibition of angiogenesis. Ectopic expression of sRIII significantly inhibited the growth of tumors formed by human colon carcinoma HCT116 and breast carcinoma MDA-MB-435 cells in nude mice. It also reduced the metastatic potential of the MDA-MB-435 cells. Thus, endogenous TGFβ appears to be necessary for the progression of these two carcinomas. Furthermore, when the tumor cells were mixed with Matrigel and embedded subcutaneously in nude mice, the blood volume in Matrigel plugs containing sRIII-expressing cells as indicated by hemoglobin levels was significantly lower than that in Matrigel plugs containing the respective control cells. Blood vessel counts in paraffin sections of the Matrigel plugs containing sRIII-expressing cells were also significantly lower than those in paraffin sections of the Matrigel plugs containing control cells. Treatment of human endothelial cells with a recombinant sRIII significantly inhibited their ability to form a capillary web structure on Matrigel. These results for the first time indicate that the sRIII-induced tumor suppression appears to be in part due to the inhibition of angiogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Andres JL, Stanley K, Cheifetz S, Massague J . 1989 J. Cell Biol. 109: 3137–3145
Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD, Pietenpol JA . 1993a Cell Growth Differ. 4: 193–201
Arteaga CL, Coffey Jr RJ, Dugger TC, McCutchen CM, Moses HL, Lyons RM . 1990 Cell Growth Differ. 1: 367–374
Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT . 1993b J. Clin. Invest. 92: 2569–2576
Bandyopadhyay A, Zhu Y, Cibull ML, Bao LW, Chen CG, Sun LZ . 1999 Cancer Res. 59: 5041–5046
Boyd DD, Levine AE, Brattain DE, McKnight MK, Brattain MG . 1988 Cancer Res. 48: 2469–2474
Brattain MG, Levine AE, Chakrabarty S, Yeoman LC, Willson JK, Long B . 1984 Cancer Metast. Rev. 3: 177–191
Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB . 1987 Cancer Res. 47: 936–942
Chen C, Wang XF, Sun LZ . 1997 J. Biol. Chem. 272: 12862–12867
Chen CR, Kang YB, Massague J . 2001 Proc. Natl. Acad. Sci. USA 98: 992–999
Chishima T, Miyagi Y, Wang X, Yamaoka H, Shimada H, Moossa AR, Hoffman RM . 1997 Cancer Res. 57: 2042–2047
Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC, Weinberg RA . 2001 Genes Dev. 15: 50–65
Esparza-Lopez J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K, Lopez-Casillas F . 2001 J. Biol. Chem. 276: 14588–14596
Fajardo LF, Prionas SD, Kwan HH, Kowalski J, Allison AC . 1996 Lab. Invest. 74: 600–608
Folkman J . 1972 Ann. Surg. 175: 409–416
Folkman J . 1995 Nat. Med. 1: 27–31
Fridman R, Kibbey MC, Royce LS, Zain M, Sweeney M, Jicha DL, Yannelli JR, Martin GR, Kleinman HK . 1991 J. Natl. Cancer Inst. 83: 769–774
Hanahan D, Folkman J . 1996 Cell 86: 353–364
Harlow E, Lane D . 1988 Antibodies – A Laboratory Manual Cold Spring Harbor Laboratory
Herbst TJ, McCarthy JB, Tsilibary EC, Furcht LT . 1988 J. Cell Biol. 106: 1365–1373
Joseph A, Weiss GH, Jin L, Fuchs A, Chowdhury S, O'Shaugnessy P, Goldberg ID, Rosen EM . 1995 J. Natl. Cancer Inst. 87: 372–377
Kleinman HK, McGarvey ML, Liotta LA, Robey PG, Tryggvason K, Martin GR . 1982 Biochemistry 21: 6188–6193
Lopez-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massague J . 1991 Cell 67: 785–795
Madri JA, Pratt BM, Tucker AM . 1988 J. Cell Biol. 106: 1375–1384
Markowitz SD, Roberts AB . 1996 Cytokine. Growth Factor. Rev. 7: 93–102
Massague J . 1990 Annu. Rev. Cell Biol. 6: 597–641
Massague J, Blain SW, Lo RS . 2000 Cell 103: 295–309
Norgaard P, Hougaard S, Poulsen HS, Spang-Thomsen M . 1995 Cancer Treat. Rev. 21: 367–403
Oft M, Heider KH, Beug H . 1998 Curr. Biol. 8: 1243–1252
Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR . 1992 Lab. Invest. 67: 519–528
Price JE . 1996 Breast Cancer Res. Treat. 39: 93–102
Price JE, Polyzos A, Zhang RD, Daniels LM . 1990 Cancer Res. 50: 717–721
Reiss M . 1999 Microbes Infect. 1: 1327–1347
Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH . 1986 Proc. Natl. Acad. Sci. USA 83: 4167–4171
Sun L, Chen C . 1997 J. Biol. Chem. 272: 25367–25372
Ueki N, Nakazato M, Ohkawa T, Ikeda T, Amuro Y, Hada T, Higashino K . 1992 Biochim. Biophys. Acta 1137: 189–196
Ueki N, Ohkawa T, Yokoyama Y, Maeda J, Kawai Y, Ikeda T, Amuro Y, Hada T, Higashino K . 1993 Jpn. J. Cancer Res. 84: 589–593
Vilchis-Landeros MM, Montiel L, Mendoza V, Mendoza-Hernandez G, Lopez-Casillas F . 2001 Biochem. J. 355: 215–222
Wang J, Sun L, Myeroff L, Wang X, Gentry LE, Yang J, Liang J, Zborowska E, Markowitz S, Willson JK, Brattain MG . 1995 J. Biol. Chem. 270: 22044–22049
Welch DR, Fabra A, Nakajima M . 1990 Proc. Natl. Acad. Sci. USA 87: 7678–7682
Yang EY, Moses HL . 1990 J. Cell Biol. 111: 731–741
Ye SC, Foster JM, Li WH, Liang JR, Zborowska E, Venkateswarlu S, Gong JG, Brattain MG, Willson JV . 1999 Cancer Res. 59: 4725–4731
Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA . 1999 J. Clin. Invest 103: 197–206
Acknowledgements
We thank Dr Janet Price for giving us MDA-MB-435 cells. F Lopez-Casíllas is an International Research Scholar of the Howard Hughes Medical Institute. This work was supported by NIH Grants CA75253 and CA79683 to L-Z Sun and CA50457 and CA72001 to MG Brattain.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bandyopadhyay, A., Zhu, Y., Malik, S. et al. Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 21, 3541–3551 (2002). https://doi.org/10.1038/sj.onc.1205439
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205439
Keywords
This article is cited by
-
Characterization of type III TGF‐β receptor expression in invasive breast carcinomas: a potential new marker and target for triple negative breast cancer
Journal of Cell Communication and Signaling (2014)
-
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors
Investigational New Drugs (2014)
-
Antiangiogenesis and antioxidant activity of ethanol extracts of Pithecellobium jiringa
BMC Complementary and Alternative Medicine (2012)
-
Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation
British Journal of Cancer (2012)
-
Antiangiogenic properties of Koetjapic acid, a natural triterpene isolated from Sandoricum koetjaoe Merr
Cancer Cell International (2011)